Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): A 12-week, phase iii, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult korean patients with mild-to-moderate hypertension

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages

  Lee, Sang Eun ^a   Kim, Yong Jin ^a   Lee, Hae Young ^a   Yang, Han Mo ^a   Park, Chang Gyu ^b   Kim, Jae Joong ^c   Kim, Soon Kil ^d   Rhee, Moo Yong ^e   Oh, Byung Hee ^a  

^a Seoul National University Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Hanyang University Guri Hospital   (South Korea)

^e Dongguk University College of Medicine   (South Korea)

Author keywords

Active control equivalence trial; Angiotensin receptor blocker; Fimasartan; Hypertension; Losartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; FIMASARTAN; LOSARTAN; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE OTITIS MEDIA; ADULT; ADVERSE OUTCOME; AGED; ALCOHOL LIVER DISEASE; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANKLE FRACTURE; ANOREXIA; ANXIETY; APPENDICITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; AUDITORY TUBE DYSFUNCTION; BACKACHE; BILIRUBIN BLOOD LEVEL; BLEPHAROSPASM; BLOOD PRESSURE REGULATION; BONE NECROSIS; BRONCHITIS; CHOLELITHIASIS; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYSTITIS; DENTAL CARIES; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSESTHESIA; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; ERECTILE DYSFUNCTION; FACE EDEMA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; FOOT FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GLUCOSE URINE LEVEL; GOUT; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEMATURIA; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPESTHESIA; INSOMNIA; INTERVERTEBRAL DISK HERNIA; JOINT EFFUSION; KERATOCONJUNCTIVITIS SICCA; KIDNEY CYST; KOREA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MUSCLE TWITCH; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NECK PAIN; NOSE DISCOMFORT; OCULAR HYPEREMIA; OCULAR PRURITUS; OTITIS MEDIA; PARESTHESIA; PELVIC DEFORMITY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLLAKISURIA; POST HOC ANALYSIS; PROSTATE HYPERTROPHY; PRURITUS; PTOSIS; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SOMNOLENCE; SPINE FRACTURE; SPINE RADIOGRAPHY; SPONDYLOSIS; STOMACH EROSION; STOMACH ULCER; SYNCOPE; TACHYCARDIA; TENDINITIS; THORAX PAIN; THROMBOCYTE COUNT; TONGUE DISCOLORATION; TRANSIENT GLOBAL AMNESIA; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERTIGO; VOMITING; WRIST FRACTURE; XEROPHTHALMIA; XEROSTOMIA;

EID: 84863363908     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.024     Document Type: Article

References (43)

1. Ezzati M., Vander Hoorn S., Lawes C.M., et al. Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med 2005, 2:e133.
2. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
3. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000, 356:1955-1964.
4. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000, 355:637-645.
5. Bian B., Kelton C.M., Guo J.J., Wigle P.R. ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm 2010, 16:671-679.
6. Conlin P.R., Gerth W.C., Fox J., et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001, 23:1999-2010.
7. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich) 2010, 12:40-46.
8. Mazzolai L., Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999, 21:23-33.
9. Weir M.R. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. Clin Ther 2007, 29:1803-1824.
10. Chrysant S.G. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. Clin Ther 2008, 30(pt 2):2181-2190.
11. Dickstein K. ELITE II and Val-HeFT are different trials: together what do they tell us?. Curr Control Trials Cardiovasc Med 2001, 2:240-243.
12. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
13. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
14. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752.
15. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752-760.
16. Fogari R., Derosa G., Ferrari I., et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 2008, 21:1034-1039.
17. Fogari R., Zoppi A., Mugellini A., et al. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2008, 51:217-222.
18. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
19. Derosa G., Maffioli P., Salvadeo S.A., et al. Candesartan effect on inflammation in hypertension. Hypertens Res 2010, 33:209-213.
20. Derosa G., Maffioli P., Salvadeo S.A., et al. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010, 33:790-795.
21. Derosa G., Maffioli P., Ferrari I., et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 2011, 34:145-151.
22. Sohn Y.T. Crystal forms of an angiotensin II receptor antagonist BR-A657. J Therm Anal Calorim 2007, 89:799-802.
23. Chi Y.H., Lee H., Paik S.H., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am J Cardiovasc Drugs 2011, 11:335-346.
24. Yi S., Kim J.W., Kim T.E., et al. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. Int J Clin Pharmacol Ther 2011, 49:321-327.
25. Yi S., Kim T.E., Yoon S.H., et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol 2011, 57:682-689.
26. Jeon H., Lim K.S., Shin K.H., et al. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers. J Cardiovasc Pharmacol 2012, 59:84-91.
27. 2011 Sartan generics enter the market of rapid growth 21tradenet, Acessed January 17, 2012. http://www.21tradenet.com/news_2011-5-26/179914.htm.
28. 2010 Forecast Insight: Antihypertensives-Fixed-dose combinations fail to offset generic erosion Datamonitor Research Store, Accessed January 17, 2012. http://www.datamonitor.com/store/Product/forecast_insight_antihypertensives_fixed_dose_combinations_fail_to_offset_generic_erosion?productid=HC00033-001.
29. Elliott W.J., Calhoun D.A., DeLucca P.T., et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001, 23:1166-1179.
30. Asmar R., Safar M., Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens 2001, 14(6 pt 1):546-552.
31. Lacourciere Y., Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/losartan study investigators. Am J Hypertens 1999, 12(12 pt 1-2):1181-1187.
32. Daniel W.W. Biostatistics: A Foundation for Analysis in the Health Sciences 2009, J. Wiley & Sons, Hoboken, NJ. 9th ed.
33. Snapinn S.M. Noninferiority trials. Curr Control Trials Cardiovasc Med 2000, 1:19-21.
34. Points to consider on switching between superiority and non-inferiority London, 2000, Acessed January 17, 2012. http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003658.
35. Gregoire J.P., Moisan J., Guibert R., et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002, 55:728-735.
36. Elliott W.J., Plauschinat C.A., Skrepnek G.H., Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007, 20:72-80.
37. Conlin P.R., Spence J.D., Williams B., et al. Angiotensin II antagonists for hypertension: are there differences in efficacy?. Am J Hypertens 2000, 13(4 Pt 1):418-426.
38. Hedner T., Oparil S., Rasmussen K., et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999, 12(4 pt 1):414-417.
39. Andersson O.K., Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998, 7:53-59.
40. Kassler-Taub K., Littlejohn T., Elliott W., et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998, 11(4 pt 1):445-453.
41. Oparil S., Guthrie R., Lewin A.J., et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998, 20:398-409.
42. Mallion J., Siche J., Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999, 13:657-664.
43. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009, 63:766-775.